Immuneering Corporation (IMRX)

Immuneering Corporation - Special Call Company Participants Benjamin Zeskind - Co-Founder, President, CEO & Director Conference Call Participants Laurence Watts Jay Olson - Oppenheimer & Co. Inc., Research Division Poorna Kannan - Needham & Company, LLC, Research Division Presentation Operator Hello, and welcome to the Immuneering conference call to discuss the positive 9-month update announced last week from the company's ongoing Phase IIa trial of atebemetinib and first-line pancreatic cancer patients. [Operator Instructions] As a reminder, this call is being recorded today, Monday, September 29, 2025.

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up.

Immuneering Corporation is upgraded to a Strong Buy due to positive phase 2a data for atebimetinib in 1st-line RAS-mutant pancreatic cancer. IMRX's atebimetinib plus mGnP achieved superior 9-month overall survival (86%) and progression-free survival (53%) compared to standard of care. Key catalysts include expected FDA feedback in Q4 2025, potential phase 3 initiation by end of 2025, and expansion into other solid tumors and NSCLC.

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Placement to Sanofi

- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to initiate pivotal trial by the end of 2025 and begin dosing patients by mid-2026 - NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced positive updated survival and safety data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients (N=34), with 9 months median follow up.

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J.

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Septe

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the closing of its previously announced private placement.

IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.

- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982).

CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a definitive securities purchase agreement for a private placement of securities to top-tier institutional and other accredited investors, that is expected to result in up front gross proceeds to the Company of approximately $25 million, before deducting fees and expenses.

- Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% overall survival (OS) observed at 6 months in ongoing Phase 2a trial of atebimetinib plus modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients (N = 34) - - Newly issued U.S. composition of matter patent for atebimetinib expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension - - Request for End of Phase 2 meeting has been submitted to the FDA; pivotal trial expected to initiate in 2026 - CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today reported financial results for the second quarter ended June 30, 2025, and provided several business updates.

- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension - - First U.S. patent granted on a deep cyclic inhibitor: a once-daily pill that aims to drive longer-lasting benefit by outpacing resistance mechanisms that cause cancer drugs to stop working - - Additional patent applications pending for atebimetinib directed to compounds, pharmaceutical compositions, and methods of use with expiration expected into 2044 - CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that the United States Patent and Trademark Office (USPTO) granted the company a composition of matter patent for atebimetinib (IMM-1-104), an oral once-daily deep cyclic inhibitor of MEK.

- 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached - - Striking tumor reductions with 39% overall response rate and 81% disease control rate observed as of the data cutoff, including many patients with deepening, durable regressions and multiple examples of individual lesions rendered undetectable - - Markedly favorable tolerability profile observed, demonstrating potential best-in-class profile - - Pivotal trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients planned for 2026 - - Company to host conference call at 8:00 a.m. ET today - CAMBRIDGE, Mass.

CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025.